A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Summary

To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA.

Timeline

Start

2025-01-15

Primary completion

2025-12-01

Completion

2026-03-01

Publications

• Li H, Xu Y, Chen Y, Ji L, Xu Y, Zheng W, Sun T, Fu R, Pei X, Liu X, Xue F, Liu W, Wang W, Chi Y, Yang R, Wei J, Zhang L. Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial. Nat Med. 2026 Jun;32(6):2026-2036. doi: 10.1038/s41591-026-04366-x. Epub 2026 Apr 29.

Drugs

Indications